Your browser doesn't support javascript.
loading
An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.
Temam, S; Spicer, J; Farzaneh, F; Soria, J C; Oppenheim, D; McGurk, M; Hollebecque, A; Sarini, J; Hussain, K; Soehrman Brossard, S; Manenti, L; Evers, S; Delmar, P; Di Scala, L; Mancao, C; Feuerhake, F; Andries, L; Ott, M G; Passioukov, A; Delord, J P.
Affiliation
  • Temam S; Department of Head and Neck Surgical Oncology, Institut Gustave Roussy, Villejuif, France. Electronic address: stephane.temam@gustaveroussy.fr.
  • Spicer J; Division of Cancer Studies.
  • Farzaneh F; Department of Haematological Medicine, King's College London, London, UK.
  • Soria JC; DITEP (Drug Development Department), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Oppenheim D; Department of Haematological Medicine, King's College London, London, UK.
  • McGurk M; Guy's & St Thomas' NHS Foundation Trust, London, UK.
  • Hollebecque A; DITEP (Drug Development Department), Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Sarini J; Department of Surgery, Institut Claudius Regaud, Toulouse, France.
  • Hussain K; Head and Neck Surgery, King's College London, Guy's Hospital Campus, London, UK.
  • Soehrman Brossard S; Roche Innovation Center Basel, Basel.
  • Manenti L; Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Evers S; Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Delmar P; Roche Innovation Center Basel, Basel.
  • Di Scala L; Roche Innovation Center Basel, Basel.
  • Mancao C; Roche Innovation Center Basel, Basel.
  • Feuerhake F; Institute for Pathology, Hannover Medical School, Hannover; Institute for Neuropathology, University Hospital Freiburg, Freiburg im Breisgau, Germany.
  • Andries L; HistoGeneX, Antwerpen, Belgium.
  • Ott MG; Roche Innovation Center Basel, Basel.
  • Passioukov A; Roche Innovation Center Zurich, Schlieren, Switzerland.
  • Delord JP; Clinical Research Unit, Institut Claudius Regaud, Toulouse, France.
Ann Oncol ; 28(11): 2827-2835, 2017 Nov 01.
Article in En | MEDLINE | ID: mdl-28950289
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Antineoplastic Combined Chemotherapy Protocols / ErbB Receptors / Head and Neck Neoplasms / Antibody-Dependent Cell Cytotoxicity Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Year: 2017 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Antineoplastic Combined Chemotherapy Protocols / ErbB Receptors / Head and Neck Neoplasms / Antibody-Dependent Cell Cytotoxicity Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Year: 2017 Document type: Article